A Triangle startup that launched last year has landed a $150 million financing deal as it moves its lead program into late-stage clinical trials.
Pathalys Pharma, led by former Liquidia CEO Neal Fowler, announced the deal this week. It includes a combination of equity and product financing. The funding will support two upcoming phase 3 studies and subsequent pre-commercialization activities for the startup's lead drug, upacicalcet.
Life sciences investment firm Abingworth led the financing, which…
